Study Examines RMS Patient Treatment Preferences Based on the Effects of Sphingosine-1-Phosphate Receptor Modulators
A recent study presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) identified key factors influencing patient preferences for different sphingosine-1-phosphate (S1P) receptor modulators for the treatment of relapsing multiple sclerosis (RMS). The most important factors selected by study participants was immune system recovery time, followed by drug-drug interactions, interactions with tyramine-rich foods, and interactions with antidepressants.
The study, which included 400 panel-selected participants, conducted a multicriteria decision analysis (MCDA) on different S1P receptor modulators for the treatment of MS, weighted by preference data acquired from an online discrete choice experiment including hypothetical, unlabeled treatments characterized by the following attributes: number of drug-drug interactions, first-dose observations, immune system recovery time, interactions with high-tyramine food, genotyping, liver function tests, eye exams, and interactions with antidepressants. Researchers utilized relative attribute importance (RAI) determined by mixed-logit model to assess patient preferences regarding treatment side effects and found that immune system recovery time was the most important factor for patients (RAI=34.6%), followed by drug-drug interactions (RAI=24.2%), interactions with tyramine-high foods (RAI=14.9%), and interactions with antidepressants (RAI=8.4%).
Researchers incorporated performance data for each attribute to develop predicted choice probabilities (PCPs) using a mixed-logit model that determined the proportion of patients expected to choose one of the real-world treatment options, and found that Ponvory (ponesimod; Janssen Pharmaceuticals/Johnson & Johnson, Beerse, Belgium) (PCP=47.7%) was preferred over Mayzent (siponimod; Novartis, Cambridge, MA) (PCP=39.9%), Gilenya (fingolimod; Novartis, Cambridge, MA) (PCP=11.4%), and Zeposia (ozanimod; Bristol Myers Squibb, New York, NY) (PCP=0.9%). The overall MCDA value score was also highest for Ponvory (5.1), followed by Mayzent (4.9), Gilenya (3.4), and Zeposia (0.8).